Registration

13:00- 14:30

Session 1: Malaria metrics: the challenges today. Chair: Marcel Hommel

Welcome Address

Malaria surveillance systems: from control to elimination
Richard Cibulskis, Global Malaria Programme WHO, Geneva

The global distribution of Plasmodium vivax and G6PD deficiency prevalence
Simon Hay, University of Oxford, UK

Challenges in surveillance and response
Laurence Slutsker, Center for Global Health CDC, Atlanta, USA

Discussion

14:30-15:00

Coffee

15:00-17:30

Session 2: R&D Agenda for malaria eradication and the science of elimination Chair: Marcel Tanner

The importance of the linkage between national and international research funders  to support malaria elimination
Hassan Mshinda,Tanzania Commission for Science and Technology, Tanzania

Targeting the parasite in the mosquito: rationale and practicality
Robert Sinden, Imperial College London, UK.

Short talk: Finding hotspots: The role of active surveillance methods in malaria control and elimination
Hugh J.W. Sturrock, University of California San Francisco, USA 

Short talk: Rapid mapping of seasonal malaria transmission risk for strategic elimination planning in Swaziland
Justin M. Cohen, Clinton Health Access Initiative, Boston, MA, United States 

Short talk: A comprehensive risk map for malaria in Kinshasa, Democratic Republic of Congo
Philipp Bless, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland  

Malaria elimination case study series: WHO and UCSF Global Health Group

Case study: Moving to malaria elimination in Cape Verde
Cristina Fontes, Minister of Health of Cape Verde and Jean Olivier Guintran, World Health Organization

Case study: Progress towards elimination: A case study of Sri Lanka
Gawrie N.L. Galappaththy, Anti-Malaria Campaign, Ministry of Health, Sri Lanka and Cara Smith Gueye, Global Health Group, University of California, San Francisco, USA 

Case study: Achieving malaria elimination and certification in Turkmenistan
Sachly Nuryeva, Ministry of Health and Medical Industry Turkmenistan
Rossitza Kurdova-Mintcheva, World Health Organization

Case study:  Eliminating malaria and preventing its reintroduction: the Mauritius case study
Shahina Aboobakar, Ministry of Health and Quality of Life, Mauritius and Allison Tatarsky, Clinton Health Access Initiative, Boston and the Global Health Group, University of California, San Francisco, USA 

Discussion

Poster Session and Welcome Reception

08:15-10:30

Session 3:Health systems and system-based interventions. Chair: Holly Williams

Health systems stewards and health systems researchers: a critical partnership for malaria elimination
Don de Savigny, Swiss Tropical & Public Health Institute, Basel, Switzerland

Communities, policy-makers and scientists: a critical partnership for malaria elimination
Halima Mwenesi, FHI 360, Washington, USA

Supply and demand for antimalarial drugs and diagnostic testing in the era of subsidies: multi-country findings
Tanya Shewchuk,ACTwatch PSI, Nairobi, Kenya

Overcoming the affordability barrier for effective and high quality life saving malaria medicines in the private sector in rural Uganda: The Consortium for ACT Private Sector Subsidy (CAPSS) pilot study
Ambrose Talisuna,Medicines for Malaria Venture (MMV); University of Oxford-KEMRI-Wellcome Trust Research Programme and Worldwide Antimalarial Resistance Network (WWARN).

Short talk: The combined effect of determinants on coverage of intermittent preventive treatment of malaria during pregnancy in the Kilombero Valley, Tanzania
Karin Gross, Swiss Tropical and Public Health Institute, Basel and University of Basel, Switzerland 

Short talk: Community directed educational intervention for malaria elimination in Bhutan: Quasi-experimental study in malaria endemic areas of sarpang district
Tashi Tobgay, Ministry of Health, Thimphu, Bhutan  

Short talk: Mystery shopping in community drug shops: research as development in rural Tanzania
Brigit Obrist, Swiss Tropical and Public Health Institute, Basel and University of Basel, Switzerland  

Coffee

11:00-12:40

Session 4: Recent research advances and The situation of P. vivax
Chair: David Rollinson 

Extended malaria parasite clearance time in African children following artemisinin-combination therapy enhances transmission to Anopheles mosquitoes
Teun Bousema, London School of Hygiene & Tropical Medicine, UK

Chemotherapeutics for eliminating Plasmodium vivax
Kevin Baird, Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia

Intravenous application of Plasmodium falciparum sporozoites in human volunteers, a new approach to study malaria
Peter Kremsner, Eberhard Karls Universität, Tübingen, Germany

Short talk: Dissecting T cell or antibody immunodominance in a complex host-pathogen system
Carla Proietti, Queensland Institute of Medical Research, Herston, Australia

Short talk: Plasmodium vivax in Papua New Guinea: high diversity and gene flow among endemic populations signal roadblocks for elimination
Cristian Koepfli, Swiss Tropical and Public Health Institute, Basel, Switzerland 

12:40

Lunch

Sponsored Round table: Interaction between iron/folic acid and malaria. Sponsored by Sight and Life

Klaus Kraemer, Sight and Life, Basel, Switzerland & Hans Verhoef, London School of Hygiene and Tropical Medicine, UK/Wageningen University, The Netherlands. Patrick E. Duffy, Chief, Laboratory of Malaria Immunology & Vaccinology, NIAID, NIH, USA. A. Hal Drakesmith, Weatherall Institute of Molecular Medicine, Experimental Medicine Division, Molecular Immunology Group, Oxford, UK  

14:00-15:35

Session 5: Diagnostic challenges. Chair: David Bell

Elimination challenges in the Pacific: vivax and submicroscopic parasitemia
James McCarthy, Queensland Institute of Medical Research, Australia

Integrating diagnostics for elimination
Chris Drakeley, London School of Hygiene & Tropical Medicine, UK

Short talk: Mass screening tools for glucose-6-phosphate dehydrogenase deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in a highly malaria-endemic area in Uganda
Mariana De Niz, London School of Hygiene and Tropical Medicine, UK  

Short talk: Utilising malariometric data in Real Time: a strategy to roll back malaria and sustain local elimination
Clive Shiff, Johns Hopkins University, Baltimore, USA 

Short talk: Molecular diagnosis for screening and elimination of malaria: performance of the first commercially-available malaria LAMP test
Iveth J. González, Foundation for Innovative New Diagnostics (FIND), Avenue de Budé 16, Geneva, CH1202, Switzerland. 

15:35-16:05

Coffee

16:05-17:40

Session 6: New drugs and drug combinations. Chair: Nicholas White

New drugs for the control and elimination of malaria: a snapshot of the pipeline
Tim Wells, MMV, Geneva, Switzerland

Antimalarial drug discovery: targeting the hypnozoite for new radical curative agents
Bryan Yeung, Novartis Institute for Tropical Diseases, Singapore

Short talk: Estimating the window of selection of antimalarial drugs using field data
Katherine Winter, Liverpool School of Tropical Medicine, UK 

Short talk: A new P. falciparum gametocyte drug screening assay based on pLDH detection
Sarah D’Alessandro, Università di Milano, Milan, Italy 

Short talk: A quinoline-based drug, MK571, inhibits P-gh1-mediated drug transport and is more toxic to choroquine resistant Plasmodium falciparum
Sonia Edaye, McGill University, Canada 

17:45-19:45

Poster Session

20:00-22:30

Conference dinner

08:15-09:50

Session 7: Artemisinin resistance. Chair: Ambrose Talisuna

The consequences of artemisinin resistance in falciparum malaria
Nicholas J. White, University of Oxford, UK

The global challenge of antimalarial drug resistance 
Robert Newman, Global Malaria Programme WHO, Geneva, Switzerland

Short talk: The power of pooled analysis: WWARN community reaches  a critical mass of data 
Philippe J Guerin, University of Oxford, UK  

Short talk: Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review
Christine Manyando, Tropical Diseases Research Centre, Ndola, Zambia  

Short talk: Fake Artesunate in Africa. A near death experience in a European traveller
Carlos J. Chaccour, Clinica Universidad de Navarra, Pamplona, Spain  

09:50-10:20

Coffee

10:20-12:10

Session 8: Vector Control. Chair: Willem Takken

Thinking outside the 'health' box: interventions for malaria control
Steve Lindsay, Durham University, UK

Characterization of the mating systems of Anopheles gambiae in malaria control perspectives
Abdoulaye Diabaté, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso

Short talk: Does mosquito mortality in WHO insecticide susceptibility tests relate to mosquito mortality in ITN experimental hut studies?
Olivier J.T. Briët, Swiss Tropical and Public Health Institute, Basel and University of Basel, Switzerland  

Short talk: Engineering mosquito population for vector control
Alekos Simoni, Imperial College London, UK 

Short talk: The SolarMal Project: innovative mosquito trapping technology for malaria control
Alexandra Hiscox, Wageningen University and Research Centre, The Netherlands

Short talk: Dramatic changes in malaria after the free distribution of mosquito nets in Papua New Guinea
Manuel W Hetzel, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea and The University of Queensland, Herston, Australia 

Sponsored talk: Making product development partnerships work. Sponsored by Syngenta

12:10 - 13:20

Lunch

13:20 - 14:55

Session 9: Towards the malaria vaccine(s) we need. Chair: David Arnot

Malaria vaccines for eradication
Pedro Alonso, Barcelona Centre for International Health Research (CRESIB), Spain

Adaptive clinical trials of three PfSPZ products for development of a whole sporozoite vaccine that prevents Plasmodium falciparum infection, disease and transmission 
Stephen Hoffman, Sanaria Inc., Rockville, USA

Short talk: A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
Arturo Reyes-Sandoval, The Jenner Institute, University of Oxford, UK 

Short talk: Measuring Force of Infection and vaccine effects on transmission stages in clinical trials of experimental malaria vaccines
Ingrid Felger, Swiss Tropical and Public Health Institute, 4002 Basel, Switzerland

Short talk: Plant-produced transmission blocking Plasmodium falciparum Pfs25 subunit and VLP based vaccine candidates
Konstantin Musiychuk, Fraunhofer USA Center for Molecular Biotechnology, USA

14:55 - 15:25

Coffee

15:25 - 17:00

Session 10: Elimination challenges. Chair: Robert Newman

Eliminating malaria in a sub-Saharan Africa: debate it or just do it?
Richard Steketee, PATH, Seattle, USA

The science of elimination in practice
Marcel Tanner, Swiss Tropical & Public Health Institute, Basel, Switzerland

Short talk: Engaging communities in elimination: needs, approaches and tools
Maxine Whittaker, Asia Pacific Malaria Elimination Network (APMEN) and University of Queensland, Australia  

Short talk: How protected are populations if transmission relapses? Insights from mathematical modeling and simulation.
Cátia Bandeiras, Instituto Gulbenkian de Ciência, Oeiras, Portugal  

Short talk: Tools for malaria elimination in the Kingdom of Saudi Arabia
Michael Coleman, Liverpool School of Tropical Medicine, UK 

Closing Remarks

*Please note this program is subject to change

Pedro Alonso, Barcelona Centre for International Health Research (CRESIB), Spain

Kevin Baird, Eijkman-Oxford Clinical Research Unit, Jakarta

Teun Bousema, London School of Hygiene & Tropical Medicine, London UK

Richard E.Cibulskis, Global Malaria Programme WHO, Geneva Switzerland

Abdoulaye Diabaté, Institut de Recherche en Sciences de la Santé, Burkina Faso

Chris Drakeley, London School of Hygiene & Tropical Medicine, London UK

Simon Hay, University of Oxford, UK

James McCarthy, Queensland Institute of Medical Research, Australia

Hassan Mshinda, Tanzania Commission for Science and Technology, Tanzania

Robert Newman, Global Malaria Programme WHO, Geneva Switzerland

Tanya Shewchuk,  ACTwatch PSI, Nairobi, Kenya

Laurence Slutsker, Centers for Disease Control and Prevention, Atlanta USA

Tim Wells, Medicines for Malaria Venture, Geneva Switzerland

Nicholas White, University of Oxford, UK

Bryan Yeung, Novartis Institute for Tropical Diseases Singapore